Evidence map›Paper›PMID 33802219›Full record

Trial reportNutrients2021

Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy.

Milica Zrnic Ciric, Miodrag Ostojic, Ivana Baralic, Jelena Kotur-Stevuljevic, Brizita I Djordjevic, Stana Markovic, Stefan Zivkovic, Ivan Stankovic

Open access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Milica Zrnic CiricDepartment of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Miodrag OstojicFaculty of Medicine, University of Belgrade, 6 Dr Subotica Street, 11000 Belgrade, Serbia.
Ivana BaralicDepartment of Pharmacy, Zvezdara University Medical Center, Dimitrija Tucovića 161, 11000 Belgrade, Serbia.
Jelena Kotur-StevuljevicDepartment of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.ORCID 0000-0002-6980-3069
Brizita I DjordjevicDepartment of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
Stana MarkovicDepartment of Pharmacy, Zvezdara University Medical Center, Dimitrija Tucovića 161, 11000 Belgrade, Serbia.
Stefan ZivkovicDepartment of Pharmacy, Zvezdara University Medical Center, Dimitrija Tucovića 161, 11000 Belgrade, Serbia.ORCID 0000-0002-3952-4560
Ivan StankovicDepartment of Bromatology, Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11221 Belgrade, Serbia.
University of Belgrade · RSKliničko Bolnički Centar Zvezdara · RSUniversity of Banja Luka · BA

Funding

Serbian Ministry of Education, Science, and Technological Development 451-03-68/2020-14/200161 and Project No III 41022
6 · The paper itself

Abstract

Dietary supplementation with sugar cane derivates may modulate low-density lipoprotein cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purpose of this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) and vitamin K2 (45 µg), could restore the disrupted physiologic relation between LDL-C and serum PCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients on chronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS (

Indexed as

Dietary SupplementsAdultAgedAged, 80 and overAnticholesteremic AgentsAtorvastatinCholesterol, LDLDouble-Blind MethodDyslipidemiasFatty AlcoholsFemaleHumansHypercholesterolemiaMaleMiddle AgedProprotein Convertase 91-octacosanolAnticholesteremic AgentsAtorvastatinCholesterol, LDLFatty AlcoholsPCSK9 protein, humanProprotein Convertase 9Vitamin K 2VitaminsLDL-COctacosanolPCSK9statinssupplementation

Identifiers

PMID33802219
PMCPMC8001635
OpenAlexW3137744259

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.